{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T18:12:43Z","timestamp":1776103963257,"version":"3.50.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T00:00:00Z","timestamp":1745020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.cllc.2025.04.008","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:52:36Z","timestamp":1745326356000},"page":"458-469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Breaking Through: Immunotherapy Innovations in Pleural Mesothelioma"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9882-9478","authenticated-orcid":false,"given":"Amalia A.","family":"Sofianidi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos K.","family":"Syrigos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin G.","family":"Blyth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5107-6430","authenticated-orcid":false,"given":"Andriani","family":"Charpidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis A.","family":"Vathiotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2025.04.008_bib0001","series-title":"Global Cancer Observatory: Cancer Today","author":"Ferlay","year":"2024"},{"key":"10.1016\/j.cllc.2025.04.008_bib0002","series-title":"Centers for Disease Control and Prevention","article-title":"Incidence of Malignant Mesothelioma, 1999\u20132018","year":"2022"},{"key":"10.1016\/j.cllc.2025.04.008_bib0003","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","article-title":"The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification","volume":"17","author":"Sauter","year":"2022","journal-title":"J Thorac Oncol."},{"key":"10.1016\/j.cllc.2025.04.008_bib0004","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.cllc.2025.04.008_bib0005","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"The Lancet"},{"key":"10.1016\/j.cllc.2025.04.008_bib0006","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.cllc.2025.04.008_bib0007","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-Line Nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.cllc.2025.04.008_bib0008","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","article-title":"Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma","volume":"135","author":"Anraku","year":"2008","journal-title":"J Thorac Cardiovasc Surg."},{"key":"10.1016\/j.cllc.2025.04.008_bib0009","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1261241","article-title":"Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma","volume":"6","author":"Marcq","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.cllc.2025.04.008_bib0010","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2020.09.026","article-title":"Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients","volume":"150","author":"Fusco","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2025.04.008_bib0011","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/bjc.2017.269","article-title":"Evaluating the effect of immune cells on the outcome of patients with mesothelioma","volume":"117","author":"Chee","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2025.04.008_bib0012","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.jtho.2019.03.029","article-title":"Potential diagnostic and prognostic role of microenvironment in malignant pleural mesothelioma","volume":"14","author":"Salaroglio","year":"2019","journal-title":"J Thorac Oncol."},{"key":"10.1016\/j.cllc.2025.04.008_bib0013","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3389\/fonc.2019.01366","article-title":"The immune microenvironment in mesothelioma: mechanisms of resistance to immunotherapy","volume":"9","author":"Chu","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.cllc.2025.04.008_bib0014","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.apsb.2020.04.004","article-title":"The Role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy","volume":"10","author":"Yang","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.cllc.2025.04.008_bib0015","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2025.04.008_bib0016","series-title":"Emerging Concepts Targeting Immune Checkpoints in Cancer and Autoimmunity","first-page":"127","article-title":"Tim-3, Lag-3, and TIGIT","volume":"410","author":"Joller","year":"2017"},{"key":"10.1016\/j.cllc.2025.04.008_bib0017","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.cllc.2025.04.008_bib0018","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2567.2005.02145.x","article-title":"The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells","volume":"115","author":"Ma\u00e7on-Lema\u00eetre","year":"2005","journal-title":"Immunology"},{"key":"10.1016\/j.cllc.2025.04.008_bib0019","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic landscape of pleural and peritoneal mesothelioma tumours","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cllc.2025.04.008_bib0020","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1183\/09031936.06.00135305","article-title":"Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses","volume":"27","author":"Hegmans","year":"2006","journal-title":"Eur Respir J."},{"key":"10.1016\/j.cllc.2025.04.008_bib0021","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1158\/1078-0432.CCR-17-3757","article-title":"Tumor-derived GM-CSF promotes granulocyte immunosuppression in mesothelioma patients","volume":"24","author":"Khanna","year":"2018","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.cllc.2025.04.008_bib0022","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/2326-6066.CIR-16-0171","article-title":"Cytotoxic T cells in PD-L1-positive malignant pleural mesotheliomas are counterbalanced by distinct immunosuppressive factors","volume":"4","author":"Awad","year":"2016","journal-title":"Cancer Immunol Res."},{"key":"10.1016\/j.cllc.2025.04.008_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1258538","article-title":"An integrated overview of the immunosuppression features in the tumor microenvironment of pancreatic cancer","volume":"14","author":"Guo","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.cllc.2025.04.008_bib0024","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-024-01549-2","article-title":"Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives","volume":"17","author":"Shen","year":"2024","journal-title":"J Hematol Oncol J Hematol Oncol"},{"key":"10.1016\/j.cllc.2025.04.008_bib0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13045-024-01544-7","article-title":"Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives","volume":"17","author":"Lin","year":"2024","journal-title":"J. Hematol Oncol J Hematol Oncol"},{"key":"10.1016\/j.cllc.2025.04.008_bib0026","doi-asserted-by":"crossref","first-page":"v477","DOI":"10.1093\/annonc\/mdz253.018","article-title":"Association of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158","volume":"30","author":"Marabelle","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2025.04.008_bib0027","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1078-0432.CCR-20-3054","article-title":"Tumor mutational burden as a predictor of immunotherapy response: is more always better?","volume":"27","author":"Strickler","year":"2021","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"key":"10.1016\/j.cllc.2025.04.008_bib0028","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/s41467-020-20469-6","article-title":"Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy","volume":"12","author":"Gromeier","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.cllc.2025.04.008_bib0029","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2025.04.008_bib0030","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabr\u00f2","year":"2018","journal-title":"Lancet Respir Med."},{"key":"10.1016\/j.cllc.2025.04.008_bib0031","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S2213-2600(21)00043-6","article-title":"Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study","volume":"9","author":"Calabr\u00f2","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.cllc.2025.04.008_bib0032","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2025.04.008_bib0033","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol Off J Eur Soc Med Oncol."},{"key":"10.1016\/j.cllc.2025.04.008_bib0034","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","article-title":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","volume":"27","author":"Forde","year":"2021","journal-title":"Nat Med."},{"key":"10.1016\/j.cllc.2025.04.008_bib0035","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003288","article-title":"JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma","volume":"9","author":"Miyamoto","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.cllc.2025.04.008_bib0036","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.cllc.2025.04.008_bib0037","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jtho.2023.11.014","article-title":"Brief report: real-world toxicity and survival of combination immunotherapy in pleural mesothelioma\u2014RIOMeso","volume":"19","author":"McNamee","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2025.04.008_bib0038","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jtho.2023.08.004","article-title":"Meta-analysis on the combination of chemotherapy with programmed death-ligand 1 and programmed cell death protein 1 blockade as first-line treatment for unresectable pleural mesothelioma","volume":"19","author":"Tagliamento","year":"2024","journal-title":"J Thorac Oncol."},{"key":"10.1016\/j.cllc.2025.04.008_bib0039","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2024.01.016","article-title":"Based on the real-world results from australia, immunotherapy is not a good option for patients with mesothelioma","volume":"19","author":"Gray","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2025.04.008_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107440","article-title":"Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma","volume":"187","author":"Dumoulin","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2025.04.008_bib0041","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.cllc.2025.04.008_bib0042","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.cllc.2025.04.008_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2016.03.001","article-title":"Analysis of expression of PTEN\/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"96","author":"Cedr\u00e9s","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2025.04.008_bib0044","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-Meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cllc.2025.04.008_bib0045","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2025.04.008_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104633","article-title":"Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1\/PD-L1 immunotherapy in non-small cell lung cancer","volume":"92","author":"Ghiringhelli","year":"2023","journal-title":"eBioMedicine"},{"key":"10.1016\/j.cllc.2025.04.008_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1121557","article-title":"Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: work still in progress","volume":"14","author":"Perrino","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.cllc.2025.04.008_bib0048","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtho.2018.10.001","article-title":"Neoantigenic potential of complex chromosomal rearrangements in mesothelioma","volume":"14","author":"Mansfield","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2025.04.008_bib0049","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jtho.2021.10.022","article-title":"Tumor junction burden and antigen presentation as predictors of survival in mesothelioma treated with immune checkpoint inhibitors","volume":"17","author":"Kosari","year":"2022","journal-title":"J. Thorac Oncol"},{"key":"10.1016\/j.cllc.2025.04.008_bib0050","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41588-019-0576-7","article-title":"Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing","volume":"52","author":"Cort\u00e9s-Ciriano","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.cllc.2025.04.008_bib0051","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1038\/s41467-021-25894-9","article-title":"9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy","volume":"12","author":"Han","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.cllc.2025.04.008_bib0052","doi-asserted-by":"crossref","unstructured":"Takeda, M.; Kasai, T.; Enomoto, Y.; et al. 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int. 2010, 60, 395\u2013399, doi:10.1111\/j.1440-1827.2010.02534.x.","DOI":"10.1111\/j.1440-1827.2010.02534.x"},{"key":"10.1016\/j.cllc.2025.04.008_bib0053","article-title":"Immunogenomic correlates of immune-related adverse events for anti\u2013programmed cell death 1 therapy","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.cllc.2025.04.008_bib0054","doi-asserted-by":"crossref","first-page":"5408","DOI":"10.1038\/s41467-019-13368-y","article-title":"Engineering dendritic cell vaccines to improve cancer immunotherapy","volume":"10","author":"Perez","year":"2019","journal-title":"Nat Commun."},{"key":"10.1016\/j.cllc.2025.04.008_bib0055","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1164\/rccm.200909-1465OC","article-title":"Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma","volume":"181","author":"Hegmans","year":"2010","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.cllc.2025.04.008_bib0056","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.201508-1573OC","article-title":"Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma","volume":"193","author":"Cornelissen","year":"2016","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.cllc.2025.04.008_bib0057","doi-asserted-by":"crossref","first-page":"525","DOI":"10.3390\/vaccines9050525","article-title":"Long-term follow-up of mesothelioma patients treated with dendritic cell therapy in three phase I\/II trials","volume":"9","author":"Dumoulin","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.cllc.2025.04.008_bib0058","unstructured":"Aerts JGJV, Belderbos R, Baas P, et al A Multicenter, randomized, phase II\/III study of dendritic cells (DC) loaded with allogeneic tumor cell lysate in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic Cell Immunotherapy for Mesothelioma (DENIM) trial. Presented at: 2023 IASLC World Conference on Lung Cancer; September 9-12, 2023; Singapore, Republic of Singapore. Abstract OA02.05."},{"key":"10.1016\/j.cllc.2025.04.008_bib0059","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.cllc.2025.04.008_bib0060","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.cllc.2025.04.008_bib0061","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1200\/JCO.2019.37.15_suppl.2511","article-title":"Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: safety and preliminary efficacy in combination with anti-PD-1 agent","volume":"37","author":"Adusumilli","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cllc.2025.04.008_bib0062","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti\u2013PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2025.04.008_bib0063","doi-asserted-by":"crossref","first-page":"eabd8836","DOI":"10.1126\/scitranslmed.abd8836","article-title":"SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models","volume":"13","author":"Hyrenius-Wittsten","year":"2021","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.cllc.2025.04.008_bib0064","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1479-5876-11-187","article-title":"Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells","volume":"11","author":"Schuberth","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.cllc.2025.04.008_bib0065","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.annonc.2020.10.474","article-title":"Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial","volume":"32","author":"Hiltbrunner","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cllc.2025.04.008_bib0066","first-page":"192","article-title":"Current advances in CAR T cell therapy for malignant mesothelioma","volume":"2","author":"Klampatsa","year":"2020","journal-title":"J Cell Immunol."},{"key":"10.1016\/j.cllc.2025.04.008_bib0067","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1363137","article-title":"CAR T-cell immunotherapy of MET-expressing malignant mesothelioma","volume":"6","author":"Thayaparan","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.cllc.2025.04.008_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104481","article-title":"Unleashing precision: a review of targeted approaches in pleural mesothelioma","volume":"203","author":"Occhipinti","year":"2024","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425000798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425000798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T20:43:03Z","timestamp":1759351383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730425000798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1525730425000798"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.04.008","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breaking Through: Immunotherapy Innovations in Pleural Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}